SL Corporation announced on the 9th that its 'pharmaceutical quality testing excluding items outside of the Ministry of Health and Welfare' sector has been suspended. The suspension amount is approximately 5.9 billion won, which is about 70% of the company's revenue from last year.
Regarding the reason for the suspension, the company noted that 'the evaluation criteria fell short for one of the ten assessment items related to the researchers' capability evaluation among the evaluation items by the licensing authority.'
SLS Bio stated that it plans to request a reevaluation of capabilities from the Ministry of Food and Drug Safety and that it will supplement the researchers' capability evaluation to meet the requirements of the Ministry.
It added that the suspension period would take a maximum of two to three weeks according to the reevaluation schedule.